title: Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.
abstract: NY-ESO-1 antigen is a prototype of a class of cancer/testis antigens. We carried out a clinical trial using NY-ESO-1 whole protein as a cancer vaccine for 13 advanced cancer patients. We have recently reported that vaccine elicited humoral and cellular immune responses in 9 cancer patients including 4 esophageal cancer patients, and clinical responses were also observed in 4 of 5 evaluable patients. In this study, we analyzed the responses in 8 esophageal cancer patients including 4 newly enrolled patients. Patients were injected subcutaneously at biweekly intervals with NY-ESO-1 recombinant protein formulated with cholesterol-bearing hydrophobized pullulan. Induction of antibody, and CD4 and CD8 T-cell responses were observed in 7, 7 and 6 patients, respectively, out of 8 patients. 1 PR, 2 SD and 2 mixed clinical responses were observed in 6 evaluable patients. No significant adverse events were observed. Furthermore, we analyzed NY-ESO-1 and MHC class I expression and the infiltration of immune cells into tumor samples obtained before and after vaccination from 4 patients by immunohistochemistry. The results showed 2 patients with disappearance of CD4 and CD8 T-cell infiltration, 1 patient with increase in the number of CD68(+) macrophages and 1 patient with tumor antigen loss in the progressive tumors following vaccinations. The induction of NY-ESO-1 immunity and some preferable clinical outcomes were observed in esophageal cancer patients by vaccination with NY-ESO-1. However, the tumors grew eventually by various mechanisms after vaccination.
authors: Department of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. hwada@gesurg.med.osaka-u.ac.jp
authors: Hisashi
authors: H
authors: Wada
authors: Eiichi
authors: E
authors: Sato
authors: Akiko
authors: A
authors: Uenaka
authors: Midori
authors: M
authors: Isobe
authors: Ryohei
authors: R
authors: Kawabata
authors: Yurika
authors: Y
authors: Nakamura
authors: Shigemichi
authors: S
authors: Iwae
authors: Kouichiro
authors: K
authors: Yonezawa
authors: Makoto
authors: M
authors: Yamasaki
authors: Hiroshi
authors: H
authors: Miyata
authors: Yuichiro
authors: Y
authors: Doki
authors: Hiroshi
authors: H
authors: Shiku
authors: Achim A
authors: AA
authors: Jungbluth
authors: Gerd
authors: G
authors: Ritter
authors: Roger
authors: R
authors: Murphy
authors: Eric W
authors: EW
authors: Hoffman
authors: Lloyd J
authors: LJ
authors: Old
authors: Morito
authors: M
authors: Monden
authors: Eiichi
authors: E
authors: Nakayama
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000628:therapy; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007150:Immunohistochemistry; D008297:Male; D008565:Membrane Proteins / Q000276:immunology*; D008875:Middle Aged
chemical_list: D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D008565:Membrane Proteins